Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Pragmatiston Mar 04, 2021 2:23pm
154 Views
Post# 32716962

RE:RE:RE:RE:Insider filings

RE:RE:RE:RE:Insider filings
Doccole wrote:
Question about the filings- Under totals for Dan and John, the balance keeps going up, and then down. The total says current units. Are they selling the heck out of new shares? Keeps showing privately carried out but their totals are lower, thoughts?



I think that SEDI reports, as separate numbers:
 
1.  shares that are owned directly by insiders; and
 
2. shares  which the insiders direct or control (e.g. Elegen, Altapharm and Schmed).
 
This would explain the variance in numbers.
 
When Antibe was first incorporated, I believe that Legault/Wallace performed their duties under personal services contracts with Schmed/Altapharm before they became full time employees.  Hence the link.
 
If you agree with  the premise that these transactions stem from Holdings divesting their Antibe shares to Holdings owners such as Wallace and Legault, then you could reasonably assume that Altapharm and Schmed are/were also Holdings owners.
<< Previous
Bullboard Posts
Next >>